Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…
Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug financing
Lucid Diligence Brief: Teva and Blackstone Life Sciences $400m duvakitug…
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A
Lucid Diligence Brief: Poplar Therapeutics $95 million Series A extension…
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and Tedopi
Lucid Diligence Brief: OSE Immunotherapeutics refocus on lusvertikimab and…
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”…
AAAAI 2026 Preview: Key Allergy, Asthma and Immunology Highlights to Watch
AAAAI 2026 at a Glance Get ready for AAAAI 2026. LucidQuest’s preview brings…
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal
Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…
Lucid Diligence Brief: Turbine $25m Series B for virtual biology
Lucid Diligence Brief: Turbine $25m Series B for virtual biology Professional…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis
Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis Professional…
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance
Lucid Diligence Brief: Innovent - Eli Lilly Global R&D Alliance…
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization
Lucid Diligence Brief: Eli Lilly Pipeline Rationalization Professional…